AU2004257228B8 - Method for assaying protein-protein interaction - Google Patents
Method for assaying protein-protein interaction Download PDFInfo
- Publication number
- AU2004257228B8 AU2004257228B8 AU2004257228A AU2004257228A AU2004257228B8 AU 2004257228 B8 AU2004257228 B8 AU 2004257228B8 AU 2004257228 A AU2004257228 A AU 2004257228A AU 2004257228 A AU2004257228 A AU 2004257228A AU 2004257228 B8 AU2004257228 B8 AU 2004257228B8
- Authority
- AU
- Australia
- Prior art keywords
- protein
- nucleotide sequence
- protease
- encodes
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 230000004850 protein–protein interaction Effects 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 263
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 240
- 238000012360 testing method Methods 0.000 claims abstract description 173
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 130
- 230000007017 scission Effects 0.000 claims abstract description 129
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 111
- 150000001875 compounds Chemical class 0.000 claims abstract description 52
- 230000003993 interaction Effects 0.000 claims abstract description 40
- 210000004027 cell Anatomy 0.000 claims description 248
- 108091005804 Peptidases Proteins 0.000 claims description 137
- 239000004365 Protease Substances 0.000 claims description 137
- 239000002773 nucleotide Substances 0.000 claims description 102
- 125000003729 nucleotide group Chemical group 0.000 claims description 102
- 230000000694 effects Effects 0.000 claims description 84
- 102000005962 receptors Human genes 0.000 claims description 83
- 108020003175 receptors Proteins 0.000 claims description 83
- 230000014509 gene expression Effects 0.000 claims description 67
- 150000007523 nucleic acids Chemical class 0.000 claims description 65
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 45
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 45
- 102000040945 Transcription factor Human genes 0.000 claims description 45
- 108091023040 Transcription factor Proteins 0.000 claims description 45
- 210000004899 c-terminal region Anatomy 0.000 claims description 43
- 102000027257 transmembrane receptors Human genes 0.000 claims description 30
- 108091008578 transmembrane receptors Proteins 0.000 claims description 30
- 108060001084 Luciferase Proteins 0.000 claims description 29
- 239000005089 Luciferase Substances 0.000 claims description 27
- 102100030671 Gastrin-releasing peptide receptor Human genes 0.000 claims description 25
- 101001010479 Homo sapiens Gastrin-releasing peptide receptor Proteins 0.000 claims description 24
- 102000037865 fusion proteins Human genes 0.000 claims description 23
- 108020001507 fusion proteins Proteins 0.000 claims description 23
- 108090000328 Arrestin Proteins 0.000 claims description 21
- 102000003916 Arrestin Human genes 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 102000017919 ADRB2 Human genes 0.000 claims description 18
- 102100020756 D(2) dopamine receptor Human genes 0.000 claims description 18
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 claims description 18
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 claims description 18
- 101000992298 Homo sapiens Kappa-type opioid receptor Proteins 0.000 claims description 17
- 102100031819 Kappa-type opioid receptor Human genes 0.000 claims description 17
- 241000723792 Tobacco etch virus Species 0.000 claims description 16
- 102100039556 Galectin-4 Human genes 0.000 claims description 13
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 13
- 230000004048 modification Effects 0.000 claims description 13
- 238000012986 modification Methods 0.000 claims description 13
- 230000006916 protein interaction Effects 0.000 claims description 13
- 102000017926 CHRM2 Human genes 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 12
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 11
- 102100024401 Alpha-1D adrenergic receptor Human genes 0.000 claims description 10
- 101000689685 Homo sapiens Alpha-1A adrenergic receptor Proteins 0.000 claims description 10
- 101000689696 Homo sapiens Alpha-1D adrenergic receptor Proteins 0.000 claims description 10
- 101000928929 Homo sapiens Muscarinic acetylcholine receptor M2 Proteins 0.000 claims description 10
- 210000001739 intranuclear inclusion body Anatomy 0.000 claims description 10
- -1 AGTRLI Proteins 0.000 claims description 9
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 9
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims description 9
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 9
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims description 8
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 241000206602 Eukaryota Species 0.000 claims description 5
- 101000807859 Homo sapiens Vasopressin V2 receptor Proteins 0.000 claims description 5
- 102100037108 Vasopressin V2 receptor Human genes 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 4
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims description 3
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 206010003445 Ascites Diseases 0.000 claims description 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 claims description 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 210000000416 exudates and transudate Anatomy 0.000 claims description 2
- 210000004915 pus Anatomy 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 102000003840 Opioid Receptors Human genes 0.000 claims 1
- 108090000137 Opioid Receptors Proteins 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 claims 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 1
- 101800001700 Saposin-D Proteins 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 230000003551 muscarinic effect Effects 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 239000012190 activator Substances 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 230000002797 proteolythic effect Effects 0.000 abstract 2
- 235000018102 proteins Nutrition 0.000 description 182
- 102000035195 Peptidases Human genes 0.000 description 106
- 235000019419 proteases Nutrition 0.000 description 99
- 230000004927 fusion Effects 0.000 description 75
- 238000003556 assay Methods 0.000 description 69
- 108091026890 Coding region Proteins 0.000 description 68
- 150000001413 amino acids Chemical group 0.000 description 54
- 108020004414 DNA Proteins 0.000 description 45
- 235000001014 amino acid Nutrition 0.000 description 44
- 239000000556 agonist Substances 0.000 description 42
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 42
- 108091028043 Nucleic acid sequence Proteins 0.000 description 37
- 101500019501 Tobacco etch virus Nuclear inclusion protein A Proteins 0.000 description 34
- 239000013598 vector Substances 0.000 description 33
- 239000013612 plasmid Substances 0.000 description 32
- 239000012634 fragment Substances 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 25
- 230000006698 induction Effects 0.000 description 25
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 22
- 229960003638 dopamine Drugs 0.000 description 21
- 239000002609 medium Substances 0.000 description 21
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 20
- 238000007792 addition Methods 0.000 description 19
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 18
- 229940039009 isoproterenol Drugs 0.000 description 18
- 239000003446 ligand Substances 0.000 description 18
- 239000012528 membrane Substances 0.000 description 18
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 108091006027 G proteins Proteins 0.000 description 16
- 108700026244 Open Reading Frames Proteins 0.000 description 16
- 238000011144 upstream manufacturing Methods 0.000 description 16
- 102000030782 GTP binding Human genes 0.000 description 15
- 108091000058 GTP-Binding Proteins 0.000 description 15
- 230000027455 binding Effects 0.000 description 14
- 108010032967 beta-Arrestin 2 Proteins 0.000 description 13
- 239000003623 enhancer Substances 0.000 description 13
- 102100029648 Beta-arrestin-2 Human genes 0.000 description 12
- 229930182555 Penicillin Natural products 0.000 description 12
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 12
- 229940049954 penicillin Drugs 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 241001126886 Tevnia Species 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- 229930182816 L-glutamine Natural products 0.000 description 9
- 102000014384 Type C Phospholipases Human genes 0.000 description 9
- 108010079194 Type C Phospholipases Proteins 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000008488 polyadenylation Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 229950010131 puromycin Drugs 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 102100029649 Beta-arrestin-1 Human genes 0.000 description 8
- 102100026189 Beta-galactosidase Human genes 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 8
- 102100038595 Estrogen receptor Human genes 0.000 description 8
- 102000017911 HTR1A Human genes 0.000 description 8
- 101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 description 8
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 8
- 108010032969 beta-Arrestin 1 Proteins 0.000 description 8
- 108010005774 beta-Galactosidase Proteins 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 7
- 229930182837 (R)-adrenaline Natural products 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 7
- 108060006698 EGF receptor Proteins 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 101800001775 Nuclear inclusion protein A Proteins 0.000 description 7
- 108091081024 Start codon Proteins 0.000 description 7
- 229960005139 epinephrine Drugs 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 6
- 108010054267 Interferon Receptors Proteins 0.000 description 6
- 102000001617 Interferon Receptors Human genes 0.000 description 6
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 210000004900 c-terminal fragment Anatomy 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 5
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 description 5
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 5
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 102000035160 transmembrane proteins Human genes 0.000 description 5
- 108091005703 transmembrane proteins Proteins 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 4
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 4
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 102000008081 Arrestins Human genes 0.000 description 3
- 108010074613 Arrestins Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102100029951 Estrogen receptor beta Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 3
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000014400 SH2 domains Human genes 0.000 description 3
- 108050003452 SH2 domains Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 3
- 229960002213 alprenolol Drugs 0.000 description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 102000052179 human IFNAR2 Human genes 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108091008803 APLNR Proteins 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 2
- 102100030949 Apelin receptor Human genes 0.000 description 2
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 101150012960 Chrm2 gene Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 101150049660 DRD2 gene Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 2
- JXYMPBCYRKWJEE-BQBZGAKWSA-N Gly-Arg-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JXYMPBCYRKWJEE-BQBZGAKWSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 108091036060 Linker DNA Proteins 0.000 description 2
- 241001452677 Ogataea methanolica Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 2
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229940116978 human epidermal growth factor Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000026792 palmitoylation Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 108091008597 receptor serine/threonine kinases Proteins 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 108020001588 κ-opioid receptors Proteins 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- VPJXQGSRWJZDOB-UHFFFAOYSA-O 2-carbamoyloxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCOC(N)=O VPJXQGSRWJZDOB-UHFFFAOYSA-O 0.000 description 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
- 102000039549 ATF family Human genes 0.000 description 1
- 108091067350 ATF family Proteins 0.000 description 1
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 1
- 102000003808 Adiponectin Receptors Human genes 0.000 description 1
- 108090000179 Adiponectin Receptors Proteins 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000018746 Apelin Human genes 0.000 description 1
- 108010052412 Apelin Proteins 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000019274 E2F Family Human genes 0.000 description 1
- 108050006730 E2F Family Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 102000008924 GPCR kinases Human genes 0.000 description 1
- 108050000878 GPCR kinases Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000691599 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 Proteins 0.000 description 1
- 101000916059 Homo sapiens C-X-C chemokine receptor type 2 Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000655540 Homo sapiens Protransforming growth factor alpha Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000825399 Homo sapiens SHC-transforming protein 1 Proteins 0.000 description 1
- 101000826376 Homo sapiens Signal transducer and activator of transcription 2 Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108050002069 Olfactory receptors Proteins 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 108050008996 P2Y purinoceptor 1 Proteins 0.000 description 1
- 102100028045 P2Y purinoceptor 2 Human genes 0.000 description 1
- 101710096700 P2Y purinoceptor 2 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 108010068563 PepT tripeptidase Proteins 0.000 description 1
- 108010002724 Pheromone Receptors Proteins 0.000 description 1
- 102000004422 Phospholipase C gamma Human genes 0.000 description 1
- 108010056751 Phospholipase C gamma Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710132631 Protein C1 Proteins 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710203837 Replication-associated protein Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 101710097834 Thiol protease Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100035100 Transcription factor p65 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 108091005722 Vomeronasal receptors Proteins 0.000 description 1
- 102100038344 Vomeronasal type-1 receptor 2 Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000723 chemosensory effect Effects 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 108010082025 cyan fluorescent protein Proteins 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000021040 cytoplasmic transport Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000001094 effect on targets Effects 0.000 description 1
- 238000001983 electron spin resonance imaging Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 108091005708 gustatory receptors Proteins 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 102000044162 human IGF1 Human genes 0.000 description 1
- 102000055074 human PLCG1 Human genes 0.000 description 1
- 102000050116 human SHC1 Human genes 0.000 description 1
- 102000051840 human STAT2 Human genes 0.000 description 1
- 102000043392 human TGFA Human genes 0.000 description 1
- 102000011941 human estrogen receptor alpha Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 108091008569 nuclear steroid hormone receptors Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 239000002427 pheromone receptor Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000003567 signal transduction assay Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48596803P | 2003-07-09 | 2003-07-09 | |
| US60/485,968 | 2003-07-09 | ||
| US51191803P | 2003-10-15 | 2003-10-15 | |
| US60/511,918 | 2003-10-15 | ||
| US56611304P | 2004-04-27 | 2004-04-27 | |
| US60/566,113 | 2004-04-27 | ||
| PCT/US2004/021887 WO2005007822A2 (en) | 2003-07-09 | 2004-07-09 | Method for assaying protein-protein interaction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2004257228A1 AU2004257228A1 (en) | 2005-01-27 |
| AU2004257228B2 AU2004257228B2 (en) | 2008-12-18 |
| AU2004257228B8 true AU2004257228B8 (en) | 2009-01-08 |
Family
ID=34084516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004257228A Expired AU2004257228B8 (en) | 2003-07-09 | 2004-07-09 | Method for assaying protein-protein interaction |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7049076B2 (enExample) |
| EP (2) | EP1644734B1 (enExample) |
| JP (1) | JP4734498B2 (enExample) |
| CN (1) | CN1894581B (enExample) |
| AT (1) | ATE534900T1 (enExample) |
| AU (1) | AU2004257228B8 (enExample) |
| CA (1) | CA2531698A1 (enExample) |
| IL (1) | IL173023A0 (enExample) |
| WO (1) | WO2005007822A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070224615A1 (en) * | 2003-07-09 | 2007-09-27 | Invitrogen Corporation | Methods for assaying protein-protein interactions |
| CN1894581B (zh) | 2003-07-09 | 2012-02-01 | 生命技术公司 | 检测蛋白-蛋白相互作用的方法 |
| EP1893627A4 (en) * | 2005-05-27 | 2009-11-11 | Sentigen Biosciences Inc | MULTIPLEXARRAY SUITABLE FOR THE INVESTIGATION OF PROTEIN-PROTEIN INTERACTIONS |
| US20090305898A1 (en) | 2005-07-21 | 2009-12-10 | Ilan Morad | Methods and Compositions for Identifying a Peptide Having an Intermolecular Interaction With a Target of Interest |
| WO2007092938A2 (en) * | 2006-02-08 | 2007-08-16 | Invitrogen Corporation | Cellular assays for signaling receptors |
| EP1996732A4 (en) | 2006-03-02 | 2010-03-31 | Uab Research Foundation | RECOGNITION AND TREATMENT AND DISCOVERY OF REMEDIES AGAINST MYCOBACTERIAL DISEASES |
| EP2002021B1 (en) * | 2006-03-16 | 2011-10-12 | Life Technologies Corporation | Methods for assaying protein-protein interaction |
| WO2007149807A1 (en) * | 2006-06-20 | 2007-12-27 | Invitrogen Corporation | Methods for identifying modifiers of gpr1 activity |
| EP2078037A4 (en) * | 2006-11-10 | 2010-01-27 | Dimerix Bioscience Pty Ltd | HETERODIMERS / OLIGOMERS OF THE RECEPTOR FOR THE THYROTROPIN RELEASING HORMONE OF THE OREXIN RECEPTOR |
| US9026409B2 (en) | 2007-08-06 | 2015-05-05 | Design Ready Controls, Inc. | Systems, methods, and software for automated design and manufacturing of HVAC control panels |
| WO2009032716A1 (en) * | 2007-09-04 | 2009-03-12 | Sanofi-Aventis | Identifying molecules that modulate protein- protein interactions using protease activated reporters |
| FR2934684B1 (fr) | 2008-07-31 | 2012-11-16 | Cis Bio Int | Methode de detection de l'internalisation de proteines membranaires. |
| CA2737669A1 (en) * | 2008-09-25 | 2010-04-01 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Combinatorial synthesis and use of libraries of short expressed nucleic acid sequences for the analysis of cellular events |
| JP5586285B2 (ja) * | 2009-03-18 | 2014-09-10 | オリンパス株式会社 | 受容体相互作用検出方法およびサイクリックａｍｐセンサータンパク質 |
| CN107899012A (zh) | 2011-01-11 | 2018-04-13 | 戴麦里克斯生物科学有限公司 | 联合疗法 |
| GB201103453D0 (en) | 2011-03-01 | 2011-04-13 | Vib Vzw | Kinase substrate sensor |
| TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
| WO2013049398A2 (en) | 2011-09-28 | 2013-04-04 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Protein-protein interaction as biomarkers |
| WO2014153044A1 (en) * | 2013-03-14 | 2014-09-25 | Temple University Of The Commonwealth System Of Higher Education | Treatment of patients with hyponatremia and cardiac disease |
| US10226528B2 (en) * | 2013-03-15 | 2019-03-12 | The Trustees Of The University Of Pennsylvania | Vaccines with biomolecular adjuvants |
| GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
| EP3103900B1 (en) * | 2014-02-07 | 2020-09-09 | Korea Research Institute Of Bioscience And Biotechnology | High-throughput analysis method of interaction between materials, using protein fusion display technique |
| US10619155B2 (en) * | 2015-03-17 | 2020-04-14 | Brown University | Methods for labeling and manipulating a cellular circuit |
| CN104991072B (zh) * | 2015-06-16 | 2017-03-29 | 西北农林科技大学 | 一种昆虫体外蛋白质相互作用检测系统的制备方法及应用 |
| CN108463229B (zh) | 2016-01-11 | 2023-10-17 | 斯坦福大学托管董事会 | 嵌合蛋白和免疫治疗方法 |
| CN109312335B (zh) | 2016-01-11 | 2023-10-24 | 斯坦福大学托管董事会 | 嵌合蛋白和调节基因表达的方法 |
| GB201609604D0 (en) * | 2016-06-01 | 2016-07-13 | Ucl Business Plc | Cell |
| CN107976411B (zh) * | 2016-10-25 | 2020-10-23 | 中国科学院微生物研究所 | 包含别构转录因子调控系统的生物传感器、试剂盒及其在小分子检测中的用途 |
| WO2019062744A1 (zh) * | 2017-09-27 | 2019-04-04 | 北京大学 | 融合多肽 |
| CN108191979B (zh) * | 2017-12-08 | 2021-01-01 | 上海晶诺生物科技有限公司 | 一种荧光互补检测人趋化因子生物学活性的方法 |
| EP3831946A4 (en) * | 2018-07-31 | 2022-08-10 | The University of Tokyo | METHOD OF MEASUREMENT OF MEMBRANE PROTEIN ACTIVITY |
| CN110853712B (zh) * | 2018-08-01 | 2022-06-07 | 清华大学 | 鉴定多对生物分子间相互作用调控因子的方法 |
| KR102317202B1 (ko) * | 2018-10-19 | 2021-10-25 | 주식회사 프로티나 | 유방암 재발 예측 방법 |
| JP2022509850A (ja) * | 2018-12-07 | 2022-01-24 | オクタント，インク． | タンパク質間相互作用スクリーニングのためのシステム |
| JP2022513606A (ja) * | 2018-12-10 | 2022-02-09 | イエール ユニバーシティ | 宿主の生理機能を形成する微生物叢代謝産物 |
| WO2022271264A1 (en) * | 2021-06-21 | 2022-12-29 | Massachusetts Institute Of Technology | Real-time g-protein coupled receptor (gpcr) linked bioluminescent sensing of biological targets and processes |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020106698A1 (en) * | 2001-01-04 | 2002-08-08 | Myriad Genetics, Incorporated | Novel yeast two-hybrid system and use thereof |
| US20020132327A1 (en) * | 1998-03-20 | 2002-09-19 | California Institute Of Technology | Method for identifying proteases, protease target sites and regulators of protease activity in cells |
| US6455300B1 (en) * | 1995-12-08 | 2002-09-24 | Han Htun | Method and compositions for monitoring DNA binding molecules in living cells |
| AU2003215660A1 (en) * | 2002-03-13 | 2003-09-22 | Axaron Bioscience Ag | Novel method for detecting and analyzing protein interactions in vivo |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2753377B1 (fr) | 1996-09-19 | 1999-09-24 | Rhone Merieux | Nouvelle association parasiticide a base de 1-n-phenylpyra- zoles et de lactones macrocycliques endectocides |
| US3737901A (en) | 1971-05-03 | 1973-06-05 | Sierra Research Corp | Redundant aircraft clock synchronization |
| JPS57139012A (en) | 1981-02-23 | 1982-08-27 | Sankyo Co Ltd | Anthelmintic composition |
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5168061A (en) * | 1986-05-15 | 1992-12-01 | Board Of Regents, The University Of Texas System | Human chorionic peptidase-1 |
| US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5283173A (en) * | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5284746A (en) * | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5439924A (en) | 1991-12-23 | 1995-08-08 | Virbac, Inc. | Systemic control of parasites |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US5814618A (en) * | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) * | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5491084A (en) * | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| NZ272574A (en) | 1995-07-14 | 1999-02-25 | Lilly Eli & Co Nz Ltd | Aqueous base suspension concentrate containing at least one ionophore antibiotic and wetting agent and/or a surfactant and xanthan gum optionally with a suspension agent, an antifreeze agent and an antifoaming agent; drench for veterinary treatment |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US5773422A (en) | 1996-01-29 | 1998-06-30 | Komer; Gene | Avermectin formulation |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| EP0959891A1 (en) | 1996-07-30 | 1999-12-01 | Ashmont Holdings Limited | Anthelmintic formulations |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| DE19654079A1 (de) | 1996-12-23 | 1998-06-25 | Bayer Ag | Endo-ekto-parasitizide Mittel |
| US6528271B1 (en) * | 1997-06-05 | 2003-03-04 | Duke University | Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia |
| US5891646A (en) * | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
| US7128915B2 (en) | 1997-09-18 | 2006-10-31 | Research Development Foundation | Membrane virus host range mutations and their uses as vaccine substrates |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| TR200001313T2 (tr) * | 1997-11-10 | 2002-06-21 | The General Hospital Corporation | Protein etkileşimlerini ve fonksiyonel ilişkileri kaydeden tarama sistemleri |
| US6117639A (en) * | 1998-08-31 | 2000-09-12 | Vertex Pharmaceuticals Incorporated | Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity |
| US6893827B1 (en) * | 2000-02-07 | 2005-05-17 | Applera Corporation | Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation |
| US20030157553A1 (en) | 2000-03-03 | 2003-08-21 | Gabriel Berstein | Methods of assaying for G protein-coupled receptor ligands and modulators |
| US6333167B1 (en) * | 2000-03-10 | 2001-12-25 | American Home Products Corp. | Methods and reagents for identifying inhibitors of proteolysis of membrane-associated proteins |
| US7018812B2 (en) * | 2000-11-03 | 2006-03-28 | Duke University | Modified G-protein coupled receptors |
| EP1205191A1 (en) | 2000-11-13 | 2002-05-15 | Centre National De La Recherche Scientifique | Targeted modification of intracellular compounds |
| US20030013137A1 (en) * | 2001-03-13 | 2003-01-16 | Barak Larry S. | Automated methods of detecting receptor activity |
| EP1421210A4 (en) * | 2001-07-31 | 2005-02-16 | Clontech Lab Inc | METHOD FOR DETECTING PROTEASE ACTIVITY IN ONE CELL |
| EP1492874B1 (en) * | 2002-03-29 | 2011-01-19 | XOMA Technology Ltd. | Multigenic vector plasmids and methods for increasing expression of recombinant polypeptides |
| EP1353182A3 (en) | 2002-04-12 | 2004-02-04 | Smithkline Beecham Corporation | Method of predicting cell-based assay results using binding profiles |
| US7001889B2 (en) | 2002-06-21 | 2006-02-21 | Merial Limited | Anthelmintic oral homogeneous veterinary pastes |
| KR100890579B1 (ko) * | 2002-08-19 | 2009-04-27 | 프로테온 주식회사 | Ｒｎａ 결합 단백질의 유전자를 융합파트너로 이용한재조합 단백질의 제조방법 |
| DE60325640D1 (de) * | 2002-10-25 | 2009-02-12 | Mds Analytical Technologies Us | Verfahren zur identifizierung von transmembranrezeptoragonisten mit reduzierter internalisierung |
| CN1894581B (zh) | 2003-07-09 | 2012-02-01 | 生命技术公司 | 检测蛋白-蛋白相互作用的方法 |
-
2004
- 2004-07-09 CN CN2004800248641A patent/CN1894581B/zh not_active Expired - Lifetime
- 2004-07-09 EP EP04756784A patent/EP1644734B1/en not_active Expired - Lifetime
- 2004-07-09 WO PCT/US2004/021887 patent/WO2005007822A2/en not_active Ceased
- 2004-07-09 AU AU2004257228A patent/AU2004257228B8/en not_active Expired
- 2004-07-09 US US10/888,313 patent/US7049076B2/en not_active Expired - Lifetime
- 2004-07-09 EP EP10186070A patent/EP2336768A1/en not_active Withdrawn
- 2004-07-09 JP JP2006518902A patent/JP4734498B2/ja not_active Expired - Lifetime
- 2004-07-09 AT AT04756784T patent/ATE534900T1/de active
- 2004-07-09 CA CA002531698A patent/CA2531698A1/en not_active Abandoned
-
2006
- 2006-01-08 IL IL173023A patent/IL173023A0/en unknown
- 2006-02-02 US US11/346,759 patent/US8017398B2/en active Active
-
2011
- 2011-08-18 US US13/212,965 patent/US20120077706A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455300B1 (en) * | 1995-12-08 | 2002-09-24 | Han Htun | Method and compositions for monitoring DNA binding molecules in living cells |
| US20020132327A1 (en) * | 1998-03-20 | 2002-09-19 | California Institute Of Technology | Method for identifying proteases, protease target sites and regulators of protease activity in cells |
| US20020106698A1 (en) * | 2001-01-04 | 2002-08-08 | Myriad Genetics, Incorporated | Novel yeast two-hybrid system and use thereof |
| AU2003215660A1 (en) * | 2002-03-13 | 2003-09-22 | Axaron Bioscience Ag | Novel method for detecting and analyzing protein interactions in vivo |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007528713A (ja) | 2007-10-18 |
| EP1644734B1 (en) | 2011-11-23 |
| WO2005007822A2 (en) | 2005-01-27 |
| US8017398B2 (en) | 2011-09-13 |
| CN1894581A (zh) | 2007-01-10 |
| EP1644734A2 (en) | 2006-04-12 |
| IL173023A0 (en) | 2006-06-11 |
| US20120077706A1 (en) | 2012-03-29 |
| US20060147975A1 (en) | 2006-07-06 |
| WO2005007822A3 (en) | 2005-03-31 |
| AU2004257228B2 (en) | 2008-12-18 |
| CA2531698A1 (en) | 2005-01-27 |
| ATE534900T1 (de) | 2011-12-15 |
| EP2336768A9 (en) | 2011-08-10 |
| EP2336768A1 (en) | 2011-06-22 |
| CN1894581B (zh) | 2012-02-01 |
| AU2004257228A1 (en) | 2005-01-27 |
| US20050100934A1 (en) | 2005-05-12 |
| EP1644734A4 (en) | 2007-04-25 |
| US7049076B2 (en) | 2006-05-23 |
| JP4734498B2 (ja) | 2011-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004257228B8 (en) | Method for assaying protein-protein interaction | |
| CN102187225B (zh) | 使用蛋白酶活化的受体鉴别调节蛋白质-蛋白质相互作用的分子 | |
| JP5303448B2 (ja) | 親和性が減少した酵素の相補性レポーター系を用いた分子相互作用の検出 | |
| EP2002021B1 (en) | Methods for assaying protein-protein interaction | |
| US20070224615A1 (en) | Methods for assaying protein-protein interactions | |
| WO2007149807A1 (en) | Methods for identifying modifiers of gpr1 activity | |
| WO2007032793A1 (en) | Multiplex array useful for assaying protein-protein interaction | |
| HK1162664B (en) | Identifying molecules that modulate protein- protein interactions using protease activated reporters | |
| WO2007002641A2 (en) | Method for identifying cart receptor and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 22, NO 50, PAGE(S) 5953 UNDER THE HEADING APPLICATIONS ACCEPTED -NAME INDEX UNDER THE NAME SENTIGEN BIOSCIENCES INC. AND THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, APPLICATION NO. 2004257228, UNDER INID (71), CORRECT THE NAME OF THE COAPPLICANTS TO READ INVITROGEN CORPORATION AND THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |